The FDA has approved Emend for injection (fosaprepitant dimeglumine, from Merck) for the prevention of chemotherapy-induced nausea and vomiting in combination with other antiemetics. Emend for injection is an intravenous prodrug of the oral formulation of Emend (aprepitant) which rapidly converts to aprepitant after administration. The injectable formulation is currently available as a single-dose vial.
Additionally, the FDA has approved a two-dose bi-pack containing two 80mg capsules of Emend in addition to the three-dose oral regimen tri-pack currently available.
For more information call (866) 342-5683 or visit www.emendforinjection.com.